Drug Trial Radar · NCT00002549
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
Last checked: Nov 19, 2026Latest source record: Dec 23, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,520
Planned (sponsor's estimate)
Start
Nov 1993
Primary completion
Not stated
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- First posted
- Jul 19, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation in treating patients with acute myelogenous leukemia.
Conditions
- Leukemia
Interventions
filgrastimBiological
busulfanDrug
cyclophosphamideDrug
cytarabineDrug
daunorubicin hydrochlorideDrug
etoposideDrug
idarubicinDrug
mesnaDrug
mitoxantrone hydrochlorideDrug
allogeneic bone marrow transplantationProcedure
autologous bone marrow transplantationProcedure
peripheral blood stem cell transplantationProcedure
radiation therapyRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
75 sites in 11 countries. Site status is shown where the registry gives one.
Universitaetsklinik
Innsbruck, Austria
Algemeen Ziekenhuis Middelheim
Antwerp, Belgium
A.Z. St. Jan
Bruges, Belgium
Hopital Universitaire Erasme
Brussels, Belgium
Institut Jules Bordet
Brussels (Bruxelles), Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
CHU Sart-Tilman
Liège, Belgium
University Hospital Rebro
Zagreb, Croatia
Medical School/University of Zagreb
Zagreb (Agram), Croatia
University Hospital - Olomouc
Olomouc, Czechia
Institute of Hematology and Blood Transfusion
Prague, Czechia
Hopital Edouard Herriot
Lyon, France
Centre Antoine Lacassagne
Nice, France
Hotel Dieu de Paris
Paris, France
Hopital Cochin
Paris, France
Hopital Necker
Paris, France
Centre Medico-Chirurgical Foch
Suresnes, France
Institut Gustave Roussy
Villejuif, France
Staedtische Kliniken Duisburg
Duisburg, Germany
Klinikum Grosshadern
Munich (Muenchen), Germany
County Hospital
Kecskemét, Hungary
Ospedale Civile Alessandria
Alessandria, Italy
Ospedale Torrette University Ancona
Ancona, Italy
Ospedale Civile Avellino
Avellino, Italy
Universita Degli Studi di Bari Policlinico
Bari, Italy
Ospedale Regionale A. Di Summa
Brindisi, Italy
Ospedale Oncologico A. Businco
Cagliari, Italy
Ospedale Ferrarotto
Catania, Italy
Ospedale Regionale A. Pugliese
Catanzaro, Italy
Centro Trapianti di Midollo Osseo
Cremona, Italy
Ospedale Santa Croce
Cuneo, Italy
Universita Degli Studi di Firenze - Policlin. di Careggi
Firenze (Florence), Italy
Ospedali Riuniti Foggia
Foggia, Italy
Ospedale S. Antonio Abate
Gallarate Varese, Italy
Ospedale San Martino/Cliniche Universitarie Convenzionale
Genoa (Genova), Italy
Ospedale Gen. Provinciale Santa Maria Goretti
Latina, Italy
Ospedale Maggiore Lodi
Lodi, Italy
Instituto Scientifico H.S. Raffaele
Milano (Milan), Italy
Ospedale Maggiore Ca Granda
Milano (Milan), Italy
Universita di Modena
Modena, Italy
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.